The New York Eye Cancer Center
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, The New York Eye Cancer Center sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
The New York Eye Cancer Center: 3 sponsored US clinical trials, none currently recruiting.
The New York Eye Cancer Center sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Conjunctival Neoplasms, with 1 trials.
Upper-quartile sponsor footprint
The New York Eye Cancer Center sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
NCT01334879
Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
NCT00750399
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
NCT00456495
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Therapeutic Areas
How the The New York Eye Cancer Center early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Conjunctival Neoplasms (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
The New York Eye Cancer Center: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
The New York Eye Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this The New York Eye Cancer Center page
3 registered trials is a research-attention snapshot, not an endorsement of The New York Eye Cancer Center or any single study.
- None of The New York Eye Cancer Center's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Conjunctival Neoplasms is the condition The New York Eye Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Conjunctival Neoplasms trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
The New York Eye Cancer Center pipeline card: 3 registered trials from official public datasets.Report a data error.